SCRIPPS MERCY HOSPITAL
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $19.9M
- Transactions
- 6,073
- Companies
- 40
- Average per transaction
- $3,285
Who reported the payments
| Abbott | $3,339,214 |
| Boston Scientific | $1,558,923 |
| Novo Nordisk AS | $1,442,321 |
| Eli Lilly | $1,385,299 |
| Edwards Lifesciences | $1,327,317 |
| Pfizer | $1,042,744 |
| Merck | $911,382 |
| AbbVie | $728,984 |
| AstraZeneca | $677,234 |
| Intercept Pharmaceuticals, Inc. | $577,081 |
| Seagen Inc. | $461,351 |
| Shockwave Medical, Inc | $439,377 |
| Regeneron | $395,213 |
| Lilly USA, LLC | $310,026 |
| Incyte Corporation | $304,819 |
| Daiichi Sankyo Inc. | $275,646 |
| Takeda Pharmaceuticals U.S.A., Inc. | $243,651 |
| Halozyme Inc | $208,689 |
| Boehringer Ingelheim | $202,220 |
| Si-bone, Inc. | $175,641 |
| Janssen Scientific Affairs, LLC | $168,000 |
| Jazz Pharmaceuticals Inc. | $163,700 |
| Johnson & Johnson | $157,150 |
| Abiomed | $155,000 |
| Jenavalve Technology, Inc. | $134,496 |
| Acutus Medical, Inc. | $127,839 |
| Gilead | $125,652 |
| Transmedics, Inc. | $116,772 |
| Medical Device Business Services, Inc. | $113,283 |
| Alnylam Pharmaceuticals Inc. | $98,700 |
| Janssen Research & Development, LLC | $98,012 |
| Agios Pharmaceuticals, Inc. | $85,250 |
| Regeneron Healthcare Solutions, Inc. | $83,500 |
| Astellas Pharma US Inc | $80,000 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $78,736 |
| Bristol Myers Squibb | $78,670 |
| Bayer | $77,310 |
| Exelixis Inc. | $76,725 |
| Providence Medical Technology, Inc. | $75,401 |
| Astrazeneca UK Limited | $75,292 |